Interesting miR-71 targets in
Abstract
MicroRNAs (miRNAs) found in animals, plants, and some viruses belongs to the heterogeneous class of non-coding RNAs (ncRNAs), which posttranscriptional regulates gene expression. They are linked to various cellular activities such as cell growth, differentiation, development and apoptosis. Also, they have been involved in cancer, metabolic diseases, viral infections and clinical trials targeting miRNAs has shown promising results. This chapter provides an overview on Taenia solium and Taenia crassiceps miRNAs, their possible biological functions, their role in host–parasite communication and their potential role as biomarkers and drug targets.
Keywords
- miRNAs
- small noncoding RNAs
- neurocysticercosis
- biomarkers
- drug target
1. Introduction
1.1 Overview of miRNAs: definition, biogenesis, and functions
MicroRNAs (miRNAs) are a major class of small noncoding RNAs (ncRNAs) found in animals, plants, and some viruses, which negatively regulate gene expression at the messenger RNA (mRNA) level [1]. The first known miRNA (lin-4) was found in the free-living nematode
It is well established that miRNA biogenesis is a complex process classified into canonical and non-canonical pathways. The canonical biogenesis is the dominant pathway by which miRNAs are processed [4]. This pathway includes three main steps: (i) In the nucleus, miRNA genes are transcript by RNA polymerase II as part of much longer RNAs called pri-miRNAs which contain one or a few stem-loop structures composed of approximately 70 nucleotides each (Figure 1). Sometimes miRNAs are transcribed as one long transcript called clusters, which may have similar seed regions, and in which case they are considered a family [5]. About half of all currently identified miRNAs are intragenic and processed mostly from introns and relatively few exons of protein coding genes, while the remaining are intergenic, transcribed independently of a host gene and regulated by their own promoters [6] (ii) Then, the microprocessor complex, consisting of an RNA binding protein DiGeorge Syndrome Critical Region 8 (DGCR8) and a ribonuclease III enzyme, Drosha trims the pri-miRNA to liberate a pre-miRNA hairpin which is actively transported to the cytoplasm by 5 (XPO5)/RanGTP complex (Figure 1) (iii) Its final maturation is processed in the cytoplasm where Dicer RNase III endonuclease cleaves the pre-miRNA into a single-stranded mature miRNA, removing the terminal loop (Figure 1) [4]. The directionality of the miRNA strand determines the name of the mature miRNA form [5]. Subsequently, with assistance from chaperone proteins (HSC70/HSP90) the mature miRNA is loaded into proteins of the Argonaute (Ago) family and assembles the RNA induced silencing complex (RISC) together to exert its further physiological functions (Figure 1). We defined the unloaded strand as passenger or star strand. The start strand that contains no mismatches are cleaved by AGO2 and degraded (Figure 1). Also, miRNA duplexes with central mismatches or non-AGO2 loaded miRNA are unwound and degraded. After being incorporated into the RISC, the mature miRNA induces posttranscriptional gene silencing by tethering RISC to be partially complementary to the target mRNA predominantly found within the 3′-untranslated regions (UTR). Targeting can also be facilitated by additional sequence elements, such as an unpaired Adenosine in the mRNA target sequence, corresponding to the nucleotide 1 in 5′ end of the mature miRNA. On the other hand, non-canonical miRNA biogenesis pathways are grouped into Drosha/DGCR8-independent and Dicer-independent pathways. In general, these pathways make use of different combinations of the proteins involved in the canonical pathway, mainly Drosha, Dicer, exportin 5, and AGO2 [4].

Figure 1.
Canonical microRNA biogenesis and mechanism of action. The biogenesis begins with the generation of the pri-miRNA transcript by RNA polymerase II in the nucleus. The microprocessor complex, composed of Drosha and DiGeorge syndrome critical region 8 (DGCR8), cleaves the pri-miRNA to produce the precursor-miRNA (pre-miRNA). After translocation into the cytoplasm by exportin 5, pre-miRNAs are processed by Dicer to form the mature miRNA/miRNA* duplex. Following processing, miRNAs are assembled into the RISC complex. Only one strand of the duplex is stably associated with the RISC complex. The mature miRNA directs repression of mRNA containing complementary miRNA binding sites within the 3’UTR.
It has been estimated that miRNAs regulate the expression of approximately one-third of the protein-coding genes [1]. Each miRNA can have many target mRNAs and a single mRNA can be regulated by multiple miRNAs [7]. Given this vast majority of mRNA targets regulated by miRNAs, aberrant miRNA expression profoundly influences a wide variety of cell regulation pathways important to cell proliferation, apoptosis, and stress responses.
Single miRNA gene can generate multiple miRNA isoforms (isomiRs). For example, the inconsistent choice of the strand loaded into AGO can generate two different functional miRNAs from both strands of the pre-miRNA duplex [8]. Imprecise cleavage of pri-miRNA by Drosha or pre-miRNA by Dicer can generate heterogeneous 5′ or 3′ ends. Another way to generate isomiRs is by RNA editing which may have a functional impact when the seed nucleotide is altered [4]. Exonuclease activity could remove nucleotides from miRNA 3′ end, and terminal nucleotide-transferase could add nucleotides to the miRNA 3′ end generating different isomiRs.
For almost a decade, some of the miRNA genes have been categorized into different groups, named miRNA families, based on the mature miRNA sequence and/or structure of pre-miRNAs [9]. Thus, means that microRNAs are grouped into families based on their targeting properties, which depend primarily on the identity of their extended seed region (miRNA nucleotides 2–8) [10]. Interestingly, it has been observed that miRNA genes in the same miRNA family are non-randomly co-localized and well organized around genes involved in infectious, immune system, sensory system and neurodegenerative diseases, development and cancer [11]. As with paralogous proteins, members of the same seed families often have at least partially redundant functions, with severe loss-of-function phenotypes apparent only after multiple family members are disrupted [12].
Biological functions of individual miRNAs have been extensively explored and have revealed the important role of miRNAs in many biological functions such as developmental timings, cell differentiation, embryogenesis, metabolism, organogenesis, and apoptosis [13]. Thus, miRNAs have been introduced as therapeutics or as targets of therapeutics for the treatment of disease [14]. Also, the existence of extracellular miRNAs has been widely reported these molecules as potential biomarkers for a variety of diseases. At present, miRNAs-mediated therapies for treatment of cancer and chronic hepatitis C virus (HCV) infection have shown promising results in human Phase I clinical trial [15].
2. miRNAs in Taenia solium and Taenia crassiceps
The presence of homologs to Drosha, Dicer, and Pasha (as identified in the
The expression profile of
The identification and characterization of miRNA targets is essential for understanding the function of these ncRNAs at molecular level. MiR-10 is the most expressed miRNA in
TsM_001055500 | Zinc finger, type RING / FYVE / PHD | — | bantam; miR-4989 |
TsM_001107400 | Ubiquitin carboxyl terminal hydrolase (inferred by orthology to a protein from | Thiol-dependent ubiquitinyl hydrolase activity | miR-36a; miR-36b |
TsM_000718200 | Ceramide glucosyltransferase (inferred by orthology to a human protein) | Transferase activity, transfer of glycosyl groups | let-7 |
TsM_000983300 | Casp, putative (inferred by orthology to a protein from S. mansoni) | — | miR-71 |
TsM_000787600 | Protein kinase-like domain. Tyrosine-protein kinase, active site. | Protein kinase activity, protein serine / threonine kinase activity, ATP binding, phosphotransferase activity, alcohol group as acceptor | miR-9 |
TsM_000964500 | IUAA Family Transporter | — | miR-10 |
TsM_000502500 | Fibroblast growth factor receptor homolog 1 (inferred by orthology to a | Protein kinase activity, protein tyrosine kinase activity, ATP binding | miR-124a; miR-124b |
TsM_000692000 | Mitochondrial coenzyme transporter A SLC25A42 (inferred by orthology to a human protein) | — | miR-61 |
Table 1.
Parasite miRNAs that are absent in the host, such as miR-71 or highly divergent (e.g let-7) from their host orthologs may be considered as selective therapeutic targets for treatment and control of helminth parasite infections. In addition, miR-71 is highly expressed in
2.1 miRNAs and immune response
Helminth’s parasites modulate immune responses in their host to prevent their elimination and establish chronic infections. Neurocysticercosis (NCC) implicates chronic parasitic disease with different variety of host and parasite interactions [35]. Clinical manifestations are mainly the result of inflammatory response to degeneration of parenchymal cysticercus [36].
Already knowing that the more abundant miRNAs (miR-10-5p, let-7-5p) putatively have target genes of immune response and that macrophages in murine cysticercosis promote Th1 or Th2 responses it was demonstrated that synthetic miR-10-5p and let-7-5p were internalized into the cytoplasm of murine peritoneal macrophages in vitro [27]. Interestingly, the down regulation of the expression of pro-inflammatory cytokines, such as Il6, Il1b, and TNF, IL-12, was reported when activated macrophages were incubated with IFN-γ and miR-10-5p or let-7-5p. Moreover, in macrophages activated with IL-4 these miRNAs reduced the expression of cytokines involved in M2/Th2 differentiation. These results were important, because murine resistant to cysticercosis display high levels of TNF, IL-12, IL1-β, and NO during early infection (Th1 response), which is associated with the elimination of larvae [44]. On the other hand, high levels of pro-inflammatory cytokines (IL-6 and TNF) cause damage to the microglia promoting autoimmune and neurodegenerative diseases [45, 46]. This tissue damage is also observed in human NCC at the beginning of larvae degeneration and in pig NCC when they are treated with praziquantel [47]. In contrast, viable larvae are associated with a long initial asymptomatic phase that correlate with undetectable inflammation in the SNC, presumably due to
The striking ability of helminth parasites in conferring protection from diseases of immune dysregulation has increased the attention into the immunomodulatory mechanisms evoked by these parasites. Administration of E-S antigens of
3. miRNAs in drug response
In 2010 Devaney and collaborators [52] speculated that the link between changes in miRNA levels and drug resistance in cancer cells may also be a feature of drug resistance in parasitic nematodes. On the other hand, few data have been published in connection with drug resistance in cestodes [53]. Our group study the miRNA expression profile of
The experiments showed that the overall miRNA profile remained unchanged under PZQ treatment, except for miR-7b that showed a sixfold enhanced expression [17] under PZQ treatment. One of the predicted miR- 7b targets was calponin, a calcium binding protein that inhibits myosin. This may be related to the expected alteration of intracellular calcium concentration produced by PZQ , a drug binding and inhibiting voltage-gated calcium channels, a key molecule for the regulation of calcium level inside the cell. Also, other targets of miR-7b are involved in several pathways such as amino acid and nucleotide metabolism, vesicular transport, signaling pathways, cell adhesion, cell growth, cell death and interaction with neuroactive ligands, suggesting the importance of this miRNA in parasite biology [17]. Calponin is one of miR- 7b predicted targets linked to calcium binding protein that inhibits myosin and may be related to the intracellular calcium concentration produced by PZQ . Other predicted targets of miR-7b are involved in several pathways such vesicular transport, signaling pathways, cell adhesion, cell growth, cell death and interaction with neuroactive ligands, suggesting the importance of this miRNA in parasite biology [17]. In these experiments other miRNAs showed differences in expression levels during treatment with PZQ , such as miR-31. This miRNA showed a decrease in the level of expression in cysticerci treated with PZQ and therefore the genes regulated by the miRNA would be overexpressed compared to the cysticerci that did not receive treatment with PZQ . Predicted target genes for this miRNA include: ABC transporters (transporters responsible for expelling different drugs out of the cell), thioredoxins (involved in drug metabolism), and the voltage-gated L-type calcium channel subunit alpha-1D, which is a probable site of action for praziquantel (PZQ) [54] Table 2. Additionally, other
Ion transporters | TsM_000896200 TsM_000896200 TsM_000025300 TsM_000025300 TsM_000783500 TsM_000896200 TsM_000436700 TsM_000598200 TsM_000845300 | Voltage-gated calcium channel 2C alpha-2 / delta | miR-307 miR-36a miR-36b miR-124b miR-124a miR-133 miR-745 miR-31 miR-2c |
Drug metabolism / enzyme conjugation | TsM_000648500 TsM_000648500 TsM_000191900 TsM_000625200 TsM_000625200 TsM_000685100 TsM_000979200 TsM_000610200 TsM_000860300 TsM_000219500 | Cytochrome b5-heme type / steroid binding Selenoprotein type 2C Rdx Thioredoxin-like fold Glutathione S-transferase 2C class S Thiolase-like Glutathione S-transferase 2C similar to C-terminal | miR-124a miR-124b miR-31 miR-2a miR-2b miR-9 miR-281 miR-307 miR-2162 miR-96 |
ABC transporters | TsM_001160500 TsM_000989600 TsM_000971500 TsM_001225200 TsM_000459700 TsM_000740200 TsM_000006800 TsM_000720400 TsM_000882500 TsM_000575300 TsM_000726600 | ABC type conveyors Type 2 ABC conveyors Type 1 2C ABC conveyors | miR-2b miR-2c miR-31 miR-61 miR-71 miR-125 miR-184 miR-219 miR-307 miR-3479b |
Table 2.
Interesting drug response miRNAs and targets in
These results prepare the way for continue with more studies in order to understand the response of miRNAs to drug treatment and the influence that these ncRNAs may have on drug action and/or drug resistance.
4. miRNAs as potential biomarkers
A biomarker is described as a feature that is objectively measured and evaluated as an indicator of many biological processes. Hunting for helminths biomarkers capable of providing diagnostic, prognostic, or therapeutic information has become a necessary but challenging work in cestodes research. MiRNAs were reported in blood – plasma, serum and other fluids like urine and saliva. This attribute has raised the interest of their use as potential biomarkers and diagnostic tools [55]. In the case of cestodes diseases the use of pathogen miRNAs as biomarkers promises the advent of highly specific and non-invasive diagnostic tools, since the miRNA repertoire of
The small size and the stability of miRNAs are two important features that permit the circulation of these molecules in biological fluids. The formation of protein–miRNA allows circulating miRNAs escape of degradation [5]. Also, the majority of miRNAs detectable in serum and saliva are found inside extracellular vesicles (EV) that could avoid miRNA degradation and serve as transport particles to facilitate miRNA actions in neighboring cells [56]. The term EV groups includes several types of vesicles among which microvesicles and exosomes are the most thoroughly characterized. In helminths parasites EVs are the preferred extracellular compartment under study and miRNAs as the most thoroughly characterized RNA biotype [57]. The identification and sequencing of
The extensive use of next generation of technologies such as miRNA microarrays and high-throughput deep sequencing techniques, translating biomarker into practice with increased diagnostic and therapeutic sensitivity and specificity would be less of a problem [62]. With respect to the use of ex-RNAs as biomarkers in NCC, to date, no laboratory assay from plasma, serum or cerebrospinal fluid has been performed. Furthermore, patient samples from different geographic regions together with specificity assessment with samples of patients would also provide a more realistic view of the potential of ex-RNAs as biomarkers of NCC.
5. miRNAs as potential drug target
The hypothesis that many
6. Conclusions
For the better understand of the pathophysiology of parasitic diseases at the molecular level is crucial identify and characterize parasite-specific miRNAs and their targets in hosts. The significant advance in biomedical research of miRNAs as target drugs and biomarkers is expected to be widely translated in the field of parasitology in the coming years. Why not think about miRNAs as a profitable approach to better diagnose and properly treat NNC? There is an increasing number of studies that are being done in
Regarding the neglected diseases, researchers have dedicated decades to the development of new drugs and identifying new biomarkers of disease progression but most researches are limited to academia indicating a gap between basic science and clinical application. Also, the use of miRNAs as a biomarker or potential drug target are poorly explored compared with cancer, neurological disorders, metabolic, cardiac and circulatory diseases.
It is expected that in future years the biological knowledge acquired on miRNAs, especially in biomedical research, could be widely translated into NNC since miRNAs could hold great potential as therapeutic and diagnosis targets for the control of diseases.
Acknowledgments
I would like to thanks Dr. Mara Rosenzvit and all the members of the BMHid laboratory (https://impam.conicet.gov.ar/bmhid/).
References
- 1.
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-297. doi:10.1016/s0092-8674(04)00045-5 - 2.
Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843-854. doi:10.1016/0092-8674(93)90529-y - 3.
Pasquinelli AE, Reinhart BJ, Slack F, et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature. 2000;408(6808):86-89. doi:10.1038/35040556 - 4.
Bartel DP. Metazoan MicroRNAs. Cell. 2018;173(1):20-51. doi: 10.1016/j.cell.2018.03.006 - 5.
O’Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front Endocrinol (Lausanne). 2018; 9:402. Published 2018 Aug 3. doi:10.3389/fendo.2018.00402 - 6.
Liu B, Shyr Y, Cai J, Liu Q . Interplay between miRNAs and host genes and their role in cancer. Brief Funct Genomics. 2018;18(4):255-266. doi:10.1093/bfgp/elz002 - 7.
Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15(8):509-524. doi:10.1038/nrm3838 - 8.
Guo L, Chen F. A challenge for miRNA: multiple isomiRs in miRNAomics. Gene. 2014;544(1):1-7. doi: 10.1016/j.gene.2014.04.039 - 9.
Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 2011;39(Database issue):D152-D157. doi:10.1093/nar/gkq1027 - 10.
Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215-233. doi:10.1016/j.cell.2009.01.002 - 11.
Mathelier A, Carbone A. Large scale chromosomal mapping of human microRNA structural clusters. Nucleic Acids Res. 2013;41(8):4392-4408. doi:10.1093/nar/gkt112 - 12.
Kamanu TK, Radovanovic A, Archer JA, Bajic VB. Exploration of miRNA families for hypotheses generation. Sci Rep. 2013; 3:2940. Published 2013 Oct 15. doi:10.1038/srep02940 - 13.
Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15(8):509-524. doi:10.1038/nrm3838 - 14.
Petrovic N, Ergun S. miRNAs as Potential Treatment Targets and Treatment Options in Cancer. Mol Diagn Ther. 2018;22(2):157-168. doi:10.1007/s40291-017-0314-8 - 15.
Chakraborty C, Sharma AR, Sharma G, Lee SS. Therapeutic advances of miRNAs: A preclinical and clinical update. J Adv Res. 2020; 28:127-138. Published 2020 Aug 29. doi: 10.1016/j.jare.2020.08.012 - 16.
Tsai IJ, Zarowiecki M, Holroyd N, et al. The genomes of four tapeworm species reveal adaptations to parasitism. Nature. 2013;496(7443):57-63. doi:10.1038/nature12031 - 17.
Pérez MG, Macchiaroli N, Lichtenstein G, et al. microRNA analysis of Taenia crassiceps cysticerci under praziquantel treatment and genome-wide identification ofTaenia solium miRNAs. Int J Parasitol. 2017;47(10-11):643-653. doi: 10.1016/j.ijpara.2017.04.002 - 18.
Cucher M, Prada L, Mourglia-Ettlin G, et al. Identification of Echinococcus granulosus microRNAs and their expression in different life cycle stages and parasite genotypes. Int J Parasitol. 2011;41(3-4):439-448. doi: 10.1016/j.ijpara.2010.11.010 - 19.
Winter AD, Weir W, Hunt M, et al. Diversity in parasitic nematode genomes: the microRNAs of Brugia pahangi andHaemonchus contortus are largely novel. BMC Genomics. 2012; 13:4. Published 2012 Jan 4. doi:10.1186/1471-2164-13-4 - 20.
Macchiaroli N, Cucher M, Zarowiecki M, Maldonado L, Kamenetzky L, Rosenzvit MC. microRNA profiling in the zoonotic parasite Echinococcus canadensis using a high-throughput approach. Parasit Vectors. 2015;8:83. Published 2015 Feb 6. doi:10.1186/s13071-015-0686-8 - 21.
Basika T, Macchiaroli N, Cucher M, et al. Identification and profiling of microRNAs in two developmental stages of the model cestode parasite Mesocestoides corti. Mol Biochem Parasitol. 2016;210(1-2):37-49. doi:10.1016/j.molbiopara.2016.08.004 - 22.
Fromm B, Worren MM, Hahn C, Hovig E, Bachmann L. Substantial loss of conserved and gain of novel MicroRNA families in flatworms. Mol Biol Evol. 2013;30(12):2619-2628. doi:10.1093/molbev/mst155 - 23.
Bai Y, Zhang Z, Jin L, et al. Genome-wide sequencing of small RNAs reveals a tissue-specific loss of conserved microRNA families in Echinococcus granulosus . BMC Genomics. 2014;15(1):736. Published 2014 Aug 29. doi:10.1186/1471-2164-15-736 - 24.
Cucher M, Macchiaroli N, Kamenetzky L, Maldonado L, Brehm K, Rosenzvit MC. High-throughput characterization of Echinococcus spp. metacestode miRNomes. Int J Parasitol. 2015;45(4):253-267. doi: 10.1016/j.ijpara.2014.12.003 - 25.
Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol. 2009; 4:199-227. doi: 10.1146/annurev.pathol.4.110807.092222 - 26.
Kabekkodu SP, Shukla V, Varghese VK, D' Souza J, Chakrabarty S, Satyamoorthy K. Clustered miRNAs and their role in biological functions and diseases. Biol Rev Camb Philos Soc. 2018;93(4):1955-1986. doi:10.1111/brv.12428 - 27.
Landa A, Navarro L, Ochoa-Sánchez A, Jiménez L. Taenia solium andTaenia crassiceps : miRNomes of the larvae and effects of miR-10-5p and let-7-5p on murine peritoneal macrophages. Biosci Rep. 2019;39(11): BSR20190152. doi:10.1042/BSR20190152 - 28.
Cai P, Hou N, Piao X, et al. Profiles of small non-coding RNAs in Schistosoma japonicum during development. PLoS Negl Trop Dis. 2011;5(8): e1256. doi: 10.1371/journal.pntd.0001256 - 29.
Zhi F, Shao N, Wang R, et al. Identification of 9 serum microRNAs as potential noninvasive biomarkers of human astrocytoma. Neuro Oncol. 2015;17(3):383-391. doi:10.1093/neuonc/nou169 - 30.
Giusti J, Pinhal D, Moxon S, Campos CL, Münsterberg A, Martins C. MicroRNA-10 modulates Hox genes expression during Nile tilapia embryonic development. Mech Dev. 2016;140:12-18. doi: 10.1016/j.mod.2016.03.002 - 31.
Mansfield JH, McGlinn E. Evolution, expression, and developmental function of Hox-embedded miRNAs. Curr Top Dev Biol. 2012; 99:31-57. doi:10.1016/B978-0-12-387038-4.00002-1 - 32.
Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans . Nature. 2000;403(6772):901-906. doi:10.1038/35002607 - 33.
Zhu H, Shyh-Chang N, Segrè AV, et al. The Lin28/let-7 axis regulates glucose metabolism. Cell. 2011;147(1):81-94. doi: 10.1016/j.cell.2011.08.033 - 34.
Pérez MG, Spiliotis M, Rego N, et al. Deciphering the role of miR-71 in Echinococcus multilocularis early development in vitro. PLoS Negl Trop Dis. 2019;13(12):e0007932. Published 2019 Dec 27. doi: 10.1371/journal.pntd.0007932 - 35.
Maizels RM, Smits HH, McSorley HJ. Modulation of Host Immunity by Helminths: The Expanding Repertoire of Parasite Effector Molecules. Immunity. 2018;49(5):801-818. doi:10.1016/j.immuni.2018.10.016 - 36.
Sikasunge CS, Johansen MV, Phiri IK, Willingham AL 3rd, Leifsson PS. The immune response in Taenia solium neurocysticercosis in pigs is associated with astrogliosis, axonal degeneration and altered blood-brain barrier permeability. Vet Parasitol. 2009;160(3-4):242-250. doi:10.1016/j.vetpar.2008.11.015 - 37.
Fleury, A., Cardenas, G., Adalid-Peralta, L., Fragoso, G., and Sciutto, E. Immunopathology in Taenia solium neurocysticercosis. Parasite Immunol. 2016; 38, 147-157. doi: 10.1111/pim.12299 - 38.
Rouas, R., Fayyad-Kazan, H., El Zein, N., Lewalle, P., Rothé, F., Simion, A., Akl, H., Mourtada, M., El Rifai, M., Burny, A., Romero, P., Martiat, P., Badran, B. Human natural Treg microRNA signature: role of microRNA-31 and microRNA21 in FOXP3 expression. Eur. J. Immunol. 2009; 39, 1608-1618 - 39.
Martínez-Saucedo D, Ruíz-Rosado JD, Terrazas C, Callejas BE, Satoskar AR, Partida-Sánchez S, Terrazas LI. Taenia crassiceps -Excreted/Secreted Products Induce a Defined MicroRNA Profile that Modulates Inflammatory Properties of Macrophages. J Immunol Res. 2019 May 14;2019:2946713. doi: 10.1155/2019/2946713 - 40.
Curtale G, Rubino M, Locati M. MicroRNAs as Molecular Switches in Macrophage Activation. Front Immunol. 2019;10:799. Published 2019 Apr 17. doi:10.3389/fimmu.2019.00799 - 41.
Davidson-Moncada, J., Papavasiliou, F. N., and Tam, W. MicroRNAs of the immune system. Ann. N.Y. Acad. Sci. 2010; 1183, 183-194. doi: 10.1111/j.1749-6632.2009.05121 - 42.
Atri C, Guerfali FZ, Laouini D. Role of Human Macrophage Polarization in Inflammation during Infectious Diseases. Int J Mol Sci. 2018;19(6):1801. Published 2018 Jun 19. doi:10.3390/ijms19061801 - 43.
Peón AN, Espinoza-Jiménez A, Terrazas LI. Immunoregulation by Taenia crassiceps and its antigens. Biomed Res Int. 2013;2013:498583. doi:10.1155/2013/498583 - 44.
Reyes JL, Terrazas CA, Vera-Arias L, Terrazas LI. Differential response of antigen presenting cells from susceptible and resistant strains of mice to Taenia crassiceps infection. Infect Genet Evol. 2009;9(6):1115-1127. doi:10.1016/j.meegid.2009.05.011 - 45.
Rothaug M, Becker-Pauly C, Rose-John S. The role of interleukin-6 signaling in nervous tissue. Biochim Biophys Acta. 2016;1863(6 Pt A):1218-1227. doi:10.1016/j.bbamcr.2016.03.018 - 46.
Probert L. TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects. Neuroscience. 2015;302:2-22. doi:10.1016/j.neuroscience.2015.06.038 - 47.
Mahanty S, Orrego MA, Mayta H, et al. Post-treatment vascular leakage and inflammatory responses around brain cysts in porcine neurocysticercosis. PLoS Negl Trop Dis. 2015;9(3):e0003577. Published 2015 Mar 16. doi:10.1371/journal.pntd.0003577 - 48.
Fleury A, Cardenas G, Adalid-Peralta L, Fragoso G, Sciutto E. Immunopathology in Taenia solium neurocysticercosis. Parasite Immunol. 2016;38(3):147-157. doi:10.1111/pim.12299 - 49.
Peón AN, Ledesma-Soto Y, Olguín JE, Bautista-Donis M, Sciutto E, Terrazas LI. Helminth Products Potently Modulate Experimental Autoimmune Encephalomyelitis by Downregulating Neuroinflammation and Promoting a Suppressive Microenvironment. Mediators Inflamm. 2017;2017:8494572. doi:10.1155/2017/8494572 - 50.
Ledesma-Soto Y, Callejas BE, Terrazas CA, et al. Extraintestinal Helminth Infection Limits Pathology and Proinflammatory Cytokine Expression during DSS-Induced Ulcerative Colitis: A Role for Alternatively Activated Macrophages and Prostaglandins. Biomed Res Int. 2015;2015:563425. doi:10.1155/2015/563425 - 51.
Rehli M., Sulzbacher S., Pape S., et al. Transcription factor Tfec contributes to the IL-4-inducible expression of a small group of genes in mouse macrophages including the granulocyte colony-stimulating factor receptor. The Journal of Immunology. 2005;174(11):7111-7122. doi: 10.4049/jimmunol.174.11.7111 - 52.
Devaney E, Winter AD, Britton C. microRNAs: a role in drug resistance in parasitic nematodes? Trends Parasitol. 2010;26(9):428-433. doi:10.1016/j.pt.2010.05.003 - 53.
Jesudoss Chelladurai J, Kifleyohannes T, Scott J, Brewer MT. Praziquantel Resistance in the Zoonotic Cestode Dipylidium caninum . Am J Trop Med Hyg. 2018;99(5):1201-1205. doi:10.4269/ajtmh.18-0533 - 54.
Greenberg RM. Ca2+ signalling, voltage-gated Ca2+ channels and praziquantel in flatworm neuromusculature. Parasitology. 2005;131 Suppl:S97-108. doi: 10.1017/S0031182005008346 - 55.
Condrat CE, Thompson DC, Barbu MG, et al. miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis. Cells. 2020;9(2):276. doi:10.3390/cells9020276 - 56.
Boon RA, Iekushi K, Lechner S, Seeger T, Fischer A, Heydt S, Kaluza D, Tréguer K, Carmona G, Bonauer A, Horrevoets AJ, Didier N, Girmatsion Z, Biliczki P, Ehrlich JR, Katus HA, Müller OJ, Potente M, Zeiher AM, Hermeking H, Dimmeler S. MicroRNA-34a regulates cardiac ageing and function. Nature. 2013 Mar 7;495(7439):107-10. doi: 10.1038/nature11919. Epub 2013 Feb 20. PMID: 23426265 - 57.
Ancarola ME, Lichtenstein G, Herbig J, et al. Extracellular non-coding RNA signatures of the metacestode stage of Echinococcus multilocularis . PLoS Negl Trop Dis. 2020;14(11):e0008890. Published 2020 Nov 30. doi:10.1371/journal.pntd.0008890 - 58.
Ding J, He G, Wu J, et al. miRNA-seq of Echinococcus multilocularis Extracellular Vesicles and Immunomodulatory Effects of miR-4989. Front Microbiol. 2019;10:2707. Published 2019 Nov 29. doi:10.3389/fmicb.2019.02707 - 59.
Liang P, Mao L, Zhang S, et al. Identification and molecular characterization of exosome-like vesicles derived from the Taenia asiatica adult worm. Acta Trop. 2019;198:105036. doi:10.1016/j.actatropica.2019.05.027 - 60.
Wang L, Li Z, Shen J, et al. Exosome-like vesicles derived by Schistosoma japonicum adult worms mediates M1 type immune- activity of macrophage. Parasitol Res. 2015;114(5):1865-1873. doi:10.1007/s00436-015-4373-7 - 61.
Ancarola ME, Marcilla A, Herz M, et al. Cestode parasites release extracellular vesicles with microRNAs and immunodiagnostic protein cargo. Int J Parasitol. 2017;47(10-11):675-686. doi:10.1016/j.ijpara.2017.05.003 - 62.
Tribolet L, Kerr E, Cowled C, et al. MicroRNA Biomarkers for Infectious Diseases: From Basic Research to Biosensing. Front Microbiol. 2020;11:1197. Published 2020 Jun 3. doi:10.3389/fmicb.2020.01197 - 63.
Broderick JA, Zamore PD. MicroRNA therapeutics. Gene Ther. 2011;18(12):1104-1110. doi:10.1038/gt.2011.50 - 64.
Baumann V, Winkler J. miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents. Future Med Chem. 2014;6(17):1967-1984. doi:10.4155/fmc.14.116 - 65.
Ryoo JH, Wang C, Swearer SM, Hull M, Shi D. Longitudinal Model Building Using Latent Transition Analysis: An Example Using School Bullying Data. Front Psychol. 2018;9:675. Published 2018 May 8. doi:10.3389/fpsyg.2018.00675 - 66.
Paul S, Ruiz-Manriquez LM, Serrano-Cano FI, Estrada-Meza C, Solorio-Diaz KA, Srivastava A. Human microRNAs in host-parasite interaction: a review. 3 Biotech. 2020;10(12):510. doi:10.1007/s13205-020-02498-6